Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS

This looks like a relatively favorable Phase 2 setup because the primary readout is safety plus immunogenicity, not hard clinical efficacy in active smallpox. Those endpoints usually carry higher success rates, especially in a likely healthy-volunteer vaccination setting. Mechanistically, the main risk is immune interference from 28 days of oral tecovirimat given with JYNNEOS, but the study is specifically designed to test that question and JYNNEOS is a vaccine platform where catastrophic interference is not the base case. The safety endpoint is also comparatively achievable unless coadministration creates a clear tolerability signal. The main uncertainty is that success probably requires both acceptable adverse-event findings and preserved immune response at Day 43, so even modest antibody blunting could create a mixed or negative interpretation. Operationally, the primary completion date is already past while the status is still Active Not Recruiting, which raises some disclosure and data-cleaning risk, but that affects timing more than the underlying probability of a positive dataset. Overall, trial facts support a better-than-even chance of a positive result.

This Phase 2 drug-vaccine interaction study (n~100) tests whether co-administration of TPOXX with JYNNEOS impairs vaccine immunogenicity. Safety data is clean—no drug-related serious adverse events were observed in the expanded 28-day safety study. The immunogenicity picture is more nuanced. Preliminary analysis showed no meaningful difference between TPOXX and placebo arms (the desired outcome), but immune responses to JYNNEOS were lower than expected in both groups, threatening the pre-specified non-inferiority statistical determination. CDC retesting of a sample subset showed the expected immune response, which is encouraging. As of Q3 2025, SIGA stated it believes TPOXX does not impact JYNNEOS immune response and continues targeting a 2026 FDA submission for PEP, suggesting internal confidence the data package will hold up. The trial is 91 days past its estimated primary completion, and CDC sample analysis collaboration continues. The biggest risk is that formal non-inferiority criteria remain unmet despite directionally supportive data. SIGA's continued regulatory pursuit and CDC corroboration tilt slightly positive, but assay variability and statistical powering concerns create material uncertainty.

This Phase 2 study evaluates TPOXX co-administration with JYNNEOS vaccine for safety and immunogenicity. The primary endpoints are adverse events (Day 59) and geometric mean titers (Day 43). Phase 2 immunogenicity studies typically aim to establish acceptable safety profiles and adequate immune responses, which are designed to be achievable. However, the key uncertainty is whether TPOXX might interfere with vaccine-induced immunity—a legitimate regulatory concern. The study is past primary completion (January 2026), so results are likely imminent. Given the co-formulation question and standard Phase 2 success rates, intrinsic probability slightly favors positive (safety acceptable, immunogenicity not substantially impaired). Market price at ~50.5% is roughly aligned with this intrinsic view.

This is a Phase 2 safety and immunogenicity study combining an approved smallpox vaccine (JYNNEOS) with an approved antiviral (TPOXX). The primary endpoints are standard safety (AEs) and immunogenicity (geometric mean titer). The core risk is not efficacy, but potential immunological interference from the drug. Prior data for both agents is strong. The study is 'Active Not Recruiting,' indicating completion of enrollment, reducing operational risk. The main disclosure risk is the binary immunogenicity readout; a neutral result (no interference) is likely positive for the combination's profile. However, Phase 2 immunogenicity studies can have variable thresholds for success.

Phase 2 safety/immunogenicity study assesses oral TPOXX (tecovirimat, FDA-approved smallpox antiviral) coadministered BID x28 days with JYNNEOS vaccine (2 SC doses 4w apart) in likely healthy volunteers. Primary endpoints: AE incidence (participants with AEs, 59 days) and Day 43 LS geometric mean titer (probably GP-neutralizing Abs). Design randomized placebo-controlled, powered for non-inferiority/similarity. TPOXX polymerase inhibitor acts post-infection; JYNNEOS non-replicating MVA unlikely interfered with (nonclinical data supportive). Established 14-day TPOXX safety; 28-day extension low risk, AE rates expected comparable. Immunogenicity suppression improbable given mechanisms. Sponsor SIGA experienced (BARDA-backed TPOXX program). Operational: NCT04957485 active not recruiting, primary overdue 91 days (Apr 2026), implying imminent topline. No execution red flags. Disclosure straightforward binary readout. Intrinsic YES (endpoints met) ~70%.

This Phase 2 open-label study assesses drug-drug interaction between TPOXX (tecovirimat) and JYNNEOS vaccine. The primary safety endpoint (AE monitoring) is low-bar; serious AEs are unlikely given both products' established safety records. The immunogenicity endpoint specifically tests for interference, requiring non-inferiority rather than superiority. Since TPOXX is a small molecule antiviral and JYNNEOS is a live non-replicating vaccine, mechanistic interference is improbable. The trial completed primary follow-up in Jan 2026 (91 days ago), with status 'Active Not Recruiting' suggesting data lock. Given the biological plausibility of no interaction and historical safety data, positive results (no safety signal + no immunogenicity interference) are highly probable. Disclosure risk is low as SIGA routinely publishes.

This Phase 2 safety and immunogenicity study (NCT04957485) completed primary data collection 91 days ago, with SIGA Technologies as sponsor. The trial design is favorable: it tests whether TPOXX interferes with JYNNEOS immunogenicity, not whether TPOXX treats smallpox. The primary endpoint uses least squared geometric mean antibody titers at Day 43—a standard, measurable biomarker. Safety endpoints (adverse events over 59 days) are also straightforward to assess. The 'Active Not Recruiting' status suggests data analysis is underway with no disclosed safety holds. Prior Phase 1/2 data for TPOXX showed acceptable safety profiles. The study enrolled healthy adults, reducing baseline variability. Immunogenicity non-inferiority trials typically succeed when the investigational drug lacks immunosuppressive mechanisms—TPOXX is an antiviral targeting p37, not immunomodulatory. Disclosure risk exists given the 3-month post-completion window, but no negative signals have emerged. The 65% YES probability reflects solid mechanistic rationale and clean execution, tempered by absence of topline readout.

The Phase 2 study NCT04957485 evaluates whether concomitant oral tecovirimat (TPOXX) affects the safety or immunogenicity of the JYNNEOS vaccine in healthy adults. The intrinsic probability of a positive result—defined as non-inferior immunogenicity and comparable safety—is very high due to robust biological and preclinical evidence. Mechanistically, JYNNEOS utilizes the Modified Vaccinia Ankara (MVA) virus, which is non-replicating in human cells. MVA enters cells and expresses viral antigens but does not assemble into extracellular enveloped virions (EEVs). Tecovirimat works by inhibiting the orthopoxvirus VP37 protein, which is required solely for wrapping the virus to form EEVs. Because MVA's antigen expression does not depend on EEV formation, tecovirimat has no target pathway to inhibit during JYNNEOS immunization. Furthermore, nonhuman primate data explicitly validates this lack of interference, showing concurrent tecovirimat does not diminish the immune response to JYNNEOS. Clinically, tecovirimat has consistently shown a benign, placebo-like tolerability profile in healthy volunteers. The primary risk to a positive readout is statistical noise given the moderate sample size (N=50 per arm), which could cause the confidence interval of the antibody titer ratio to miss a strict non-inferiority margin. Overall, the foundational biology and prior data strongly support trial success.

The trial is actively assessing the safety and immunogenicity of TPOXX when administered with JYNNEOS. The study's primary endpoint focuses on adverse events and immunogenicity, which are critical for determining the efficacy and safety of the drug. Given that the trial is in Phase 2 and is currently active but not recruiting, it suggests that initial results have been promising enough to proceed to further evaluation. The indication for smallpox, a serious and potentially deadly disease, and the involvement of a reputable sponsor, SIGA Technologies, add to the likelihood of positive results. However, the relatively early stage of completion and the inherent risks in biotech trials keep the confidence level at 70.